参考文献(向下滑动) [1] Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood. 1997;89(6):2079-2088. [2] Greenberg PL, Tuechler H, Schanz J, et al. Revised in...
1.MDS prognosis: Outlook and life expectancy.Medical News Today.com 2.Valent, Orazi A.et al.Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.Oncotarget. 2017 Jul 5;8(43):73483-73500. 3. How I use molecular genetic tests to evaluate pat...
Myelodysplastic syndrome (MDS) is a very heterogeneous clonal disorder. Patients with “higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor prognosis because of a high risk of progression to secondary acute myeloid leukemia with low chemosensitivity. Allogeneic hematopoietic...
Risk assessment tools are available both to classify the stage and prognosis of MDS and to meet the needs of elderly patients. A tool explicitly focussing on elderly MDS patients, however, is still missing. The current report approached this issue by combining the well established MDS-risk score...
et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997). Article CAS PubMed Google Scholar Agarwal, A. et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and ...
International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood. 1998;91:1100) Blood, 89 (1997), pp. 2079-2088 View PDFView articleCrossrefView in ScopusGoogle Scholar 2 C.S. Cutler, S.J. Lee, P. Greenberg, et al. A decision analysis of allogen...
Patients with del(5q) are commonly believed to be the MDS subgroup with the most favorable prognosis. Nevertheless, progres- sion to AML and OS are highly dependent on additional individual risk factors. In our previous retrospective study of the multicenter registry, outcomes and prognostic ...
骨髓增生异常综合征(MDS)是一组起源于造血干细胞的异质性髓系克隆性疾病,其特点是髓系细胞发育异常,表现为无效造血、难治性血细胞减少,高风险向急性髓系白血病(AML)转化。 图源网络 风险分层对于评估MDS患者疾病危险度、生存期和制定治疗策略具有重要指导意...
In MDS patients treated with allogeneic HSCT, IPSS-R significantly improved the prediction of patient prognosis with respect to IPSS. Compared with the IPSS-based stratification, the IPSS-R risk group changed in ∼65% of patients, and the great majority of these individuals were classified into...
43 The prognosis of patients with RCMD is similar to the prognosis of other MDS patients with <5% marrow blasts, bearing in mind the prognostic impact of individual cytogenetic59 and molecular characteristics.34 The expert panel agreed that the recommendations for HSCT in RCMD should follow the ...